What has changed in AML treatment in the last 30 years?
Oncogenic mutational networks in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL
Achieving deep responses in previously treated CLL patients
Advances in acute myeloid leukemia (AML) treatment – updating 7+3